AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury

by Ysios Capital

Financing co-led by new investors LSP and Andera Partners, with participation of existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthca...

Read more

Pfizer secures exclusive option to acquire gene therapy company vivet therapeutics

by Ysios Capital

Vivet is supported by international life science investors including Novartis Venture Fund, Roche Venture Fund, HealthCap, Columbus Venture Partners, Ysios Capital, Kurma Partners and Idinvest Partner...

Read more

Minoryx Therapeutics raises €21.3M in Series B funding round

by Ysios Capital

The funding round was led by Fund+, joined by SFPI-FPIM, S.R.I.W. and Sambrinvest, in addition to all Series A investors (Ysios Capital, Kurma Partners, Roche Venture Fund, Idinvest Partners, Chiesi V...

Read more

Ysios Capital strengthens its team with the appointment of Guillem Laporta as Principal and two new Venture Partners

by Ysios Capital

Ysios Capital, a leading biotechnology venture capital firm in Spain, has announced that it has appointed Guillem Laporta as Principal and two new Venture Partners: Lance Berman and Claudia D’August...

Read more

Lundbeck to acquire Prexton Therapeutics, participated by Ysios Capital, in a deal valued at up to €905 million

by Ysios Capital

H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) have announced the signing of a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck wil...

Read more

QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing

by Ysios Capital

QIAGEN N.V. has announced it has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular...

Read more

Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs. Ysios Capital participates in the round

by Ysios Capital

The funding round was led by a global strategic investor with participation from venture capital fund Ysios Capital and a number of large private investors. Existing institutional investors (LSP, Kurm...

Read more

Ysios Capital invierte € 2,2 millones en Babyscripts, de EE.UU

by Ysios Capital

La inversión de Ysios se enmarca en la segunda ronda de financiación de Babyscripts, en la que ha captado 5,5 millones de dólares en total. Así, 2,5 millones han sido aportados por Ysios y el rest...

Read more

Anaconda Biomed Secures 15 Million Euro in Series A Financing Led by Ysios Capital, Innogest Capital and Omega Funds

by Ysios Capital

Anaconda Biomed Secures 15 Million Euro in Series A Financing Led by Ysios Capital, Innogest Capital and Omega Funds

Read more

BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital

by Ysios Capital

BioClin Therapeutics, Inc., a privately-­‐held clinical stage drug development company developing a first-­‐in-­‐class anti-­‐FGFR3 (fibroblast growth factor receptor 3) monoclonal antibod...

Read more

Prexton Therapeutics - participated by Ysios Capital - Series B financing round raises € 29 millions to advance its novel Parkinson’s therapeutic

by Ysios Capital

Forbion Capital Partners (NL) and Seroba Life Sciences (IE) co-led the financing round, which includes current investors Merck Ventures (NL), Ysios Capital (ES) and Sunstone Capital (DK). Marco Boorsm...

Read more
Subscribe to Directory
Write an Article

Highlight

3i closes second European CLO, Harvest V...

by 3i Group

3i Group plc (“3i” or “3i Group”), an international investor, ...

Clave ha lanzado su cuarto fondo de tran...

by Clave Mayor

Este nuevo fondo, según informa la compañía en un comunicado, es ...

Photos Stream